Company News for November 24, 2010 - Corporate Summary

• Eli Lilly LLY received FDA approval for its topical solution drug Axiron, for testosterone replacement therapy in men

• Tiffany TIF reported estimate-beating third quarter earnings of $0.43 a share, ahead of Zacks projections of $0.37, on a 14% revenue jump to $681.7 million that was above Zacks estimates of $651 million. The firm said it sees current year earnings of $2.72 to $2.77 a share

• Deere DE reported better-than-anticipated fiscal fourth quarter earnings of $1.07, up from Zacks estimates of $0.96, as revenues rose 38.9% to $6.56 billion, below Zacks projections of $6.66 billion

• Oracle ORCL received a jury award of $1.3 billion in its suit against SAP SAP

• FBR reiterated its "underperform" rating on Diamond Offshore DO, with a price target of $56

• JP Morgan JPM downgraded Rovi ROVI from "overweight" to "neutral," with a price target of $65

• FBR maintained a "market perform" on Jefferies JEF, with a price target of $25

• Wells Fargo WFC initiated coverage of Tower International TOWR at "outperform," with a price target range of $16-$18

• Goldman Sachs GS started coverage of Bemis BMS at "neutral," with a price target of $35

 
BEMIS (BMS): Free Stock Analysis Report
 
DEERE & CO (DE): Free Stock Analysis Report
 
DIAMOND OFFSHOR (DO): Free Stock Analysis Report
 
GOLDMAN SACHS (GS): Free Stock Analysis Report
 
JEFFERIES GP-NW (JEF): Free Stock Analysis Report
 
JPMORGAN CHASE (JPM): Free Stock Analysis Report
 
LILLY ELI & CO (LLY): Free Stock Analysis Report
 
ORACLE CORP (ORCL): Free Stock Analysis Report
 
ROVI CORP (ROVI): Free Stock Analysis Report
 
SAP AG ADR (SAP): Free Stock Analysis Report
 
TIFFANY & CO (TIF): Free Stock Analysis Report
 
WELLS FARGO-NEW (WFC): Free Stock Analysis Report
 
Zacks Investment Research